Target intelligence / Profile preview

Titin PEVK region (PEVK)

Target
PEVK
Molecular classification
Other, Structural protein, Intrinsically disordered protein, Myofilament protein
01

Overview

The Titin PEVK region is a specialized, intrinsically disordered domain within the giant protein titin (also known as connectin), located in the I-band of the muscle sarcomere (UniProt Q8WZ42). It is characterized by a high density of proline (P), glutamate (E), valine (V), and lysine (K) residues, which allow it to act as an entropic spring that provides passive tension during muscle elongation (Linke & Hamdani, 2014). This region is a major determinant of myocardial diastolic stiffness and is highly regulated by post-translational modifications, particularly phosphorylation by kinases such as protein kinase G (PKG), protein kinase A (PKA), and protein kinase C (PKC) (Hamdani et al., 2013). In diseases like heart failure with preserved ejection fraction (HFpEF), the PEVK region is often hypophosphorylated, contributing to increased ventricular stiffness and diastolic dysfunction (Borbély et al., 2005). While direct-binding small molecules for the PEVK region are not yet in clinical use, it is a primary downstream target for heart failure therapies that enhance cGMP-PKG signaling, such as neprilysin inhibitors and soluble guanylate cyclase stimulators. Understanding the mechanical properties and regulatory pathways of the PEVK region is essential for developing precision treatments for cardiomyopathies and other muscle-related disorders.

Other names
PEVK domainProline-glutamate-valine-lysine-rich regionTitin spring elementConnectin PEVK region
02

Mechanism of action

Modulation of passive myocardial stiffness through the regulation of phosphorylation sites within the PEVK domain by cGMP/PKG and cAMP/PKA signaling pathways.

03

Biological functions

OtherMuscle elasticityPassive tension regulationMechanotransductionSarcomere organization
04

Disease associations

Cardiovascular diseaseOtherSkeletal myopathyDilated cardiomyopathyHypertrophic cardiomyopathy
05

Safety considerations

Potential for systemic skeletal muscle weaknessHypotension due to systemic activation of upstream kinasesRisk of excessive cardiac wall compliance
06

Interacting drugs

Sacubitril

4 more in the full profile.

07

Biomarkers

Titin N-terminal fragmentsPEVK phosphorylation statusLeft ventricular end-diastolic stiffness (E/e' ratio)

Beyond the preview

Go deeper on Titin PEVK region (PEVK).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Titin PEVK region (PEVK).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call